Fractyl Health’s (GUTS) Buy Rating Reaffirmed at HC Wainwright

Fractyl Health (NASDAQ:GUTS)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $8.00 target price on the stock.

Several other equities analysts have also commented on the company. Canaccord Genuity Group reissued a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a report on Thursday, March 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Fractyl Health in a report on Monday, December 29th. Finally, Morgan Stanley lowered Fractyl Health from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $8.00 to $2.00 in a report on Thursday, January 29th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Fractyl Health has an average rating of “Hold” and an average price target of $5.40.

Fractyl Health Stock Down 1.6%

Shares of NASDAQ GUTS opened at $0.58 on Friday. The stock has a market cap of $92.18 million, a P/E ratio of -0.32 and a beta of 1.20. The company has a current ratio of 4.78, a quick ratio of 4.78 and a debt-to-equity ratio of 3.23. Fractyl Health has a 12-month low of $0.38 and a 12-month high of $3.03. The business’s fifty day simple moving average is $0.48 and its 200-day simple moving average is $1.19.

Fractyl Health (NASDAQ:GUTS) last announced its quarterly earnings data on Tuesday, March 24th. The company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.34. As a group, equities analysts predict that Fractyl Health will post -0.67 EPS for the current fiscal year.

Hedge Funds Weigh In On Fractyl Health

Several hedge funds have recently made changes to their positions in the company. Nantahala Capital Management LLC purchased a new position in shares of Fractyl Health during the third quarter worth about $19,298,000. 683 Capital Management LLC grew its holdings in shares of Fractyl Health by 30.1% during the fourth quarter. 683 Capital Management LLC now owns 6,047,620 shares of the company’s stock worth $13,305,000 after purchasing an additional 1,397,620 shares during the last quarter. Marshall Wace LLP grew its holdings in shares of Fractyl Health by 234.9% during the fourth quarter. Marshall Wace LLP now owns 5,926,745 shares of the company’s stock worth $13,039,000 after purchasing an additional 4,156,969 shares during the last quarter. Alyeska Investment Group L.P. purchased a new position in shares of Fractyl Health during the third quarter worth about $8,981,000. Finally, Woodline Partners LP grew its holdings in shares of Fractyl Health by 821.1% during the third quarter. Woodline Partners LP now owns 5,506,534 shares of the company’s stock worth $8,755,000 after purchasing an additional 4,908,693 shares during the last quarter.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.